Modulation of human type II secretory phospholipase A2 by sphingomyelin and annexin VI.
Conjectural results have been reported on the capacity of inflammatory secreted phospholipase A2 (sPLA2) to hydrolyse mammalian membrane phospholipids. Development of an assay based on the release of non-esterified fatty acids by the enzyme acting on the organized phospholipid mixture constituting the membrane matrix has led to the identification of two prominent effectors, sphingomyelin (SPH) and annexin. Recombinant human type II sPLA2 hydrolyses red-cell membrane phospholipids with a marked preference for the inner leaflet. This preference is apparently related to the high content of SPH in the outer leaflet, which inhibits sPLA2. This inhibition by SPH is specific for sPLA2. Cholesterol counteracts the inhibition of sPLA2 by SPH, suggesting that the SPH-to-cholesterol ratio accounts in vivo for the variable susceptibility of cell membranes to sPLA2. Different effects were observed of the presence of the non-hydrolysable D-alpha-dipalmitoyl phosphatidylcholine (D-DPPC), which renders the membranes rigid but does not inhibit sPLA2. Annexin VI was shown, along with other annexins, to inhibit sPLA2 activity by sequestering the phospholipid substrate. The present study has provided the first evidence that annexin VI, in concentrations that inhibit hydrolysis of purified phospholipid substrates, stimulated the hydrolysis of membrane phospholipids by sPLA2. The activation requires the presence of membrane proteins. The effect is specific for type II sPLA2 and is not reproducible with type I PLA2. The activation by annexin VI of sPLA2 acting on red cell membranes results in the preferential release of polyunsaturated fatty acids. It suggests that type II sPLA2, in conjunction with annexin VI, might be involved in the final step of endocytosis and/or exocytosis providing the free polyunsaturated fatty acids acting synergistically to cause membrane fusion.
Koumanov
K
K
Laboratoire de Biochimie, URA CNRS 1283, Faculté de Médecine Saint Antoine, Université Pierre et Marie Curie, Paris, France.
Wolf
C
C
Béreziat
G
G
D017317:Annexin A6 / Q000097:blood / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D005227:Fatty Acids / Q000097:blood; D006801:Humans; D006868:Hydrolysis / Q000187:drug effects; D010713:Phosphatidylcholines / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000097:blood / Q000187:drug effects*; D054467:Phospholipases A2; D010743:Phospholipids / Q000097:blood; D013109:Sphingomyelins / Q000097:blood / Q000494:pharmacology*; D013379:Substrate Specificity
D017317:Annexin A6; D005227:Fatty Acids; D010713:Phosphatidylcholines; D010743:Phospholipids; D013109:Sphingomyelins; D010741:Phospholipases A; D054467:Phospholipases A2